Loss of function mutations in ANGPTL3 also correlate with decreased risk of ASCVD in epidemiological studies, while inhibition of ANGPTL3 in atherosclerosis-prone mice with the fully human IgG4 monoclonal antibody evinacumab was associated with reductions in atherosclerotic lesions [55]. Here, ANGPTL3 is linked to atherosclerosis.